The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers ...
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 ...
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
Once a drug lost primary patent protection or hit a certain age, it was managed for steady — if declining — cash flow with ...
Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can ...
A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way ...
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” ...
Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with ...
While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a ...
The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.
Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results